NXTC$5.74+0.70%
NextCure, Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$26.25M
Float & O/S:
Inst Own:
DilutionScan read 30 of NextCure, Inc.'s SEC filings and found 3 warrant series, 2 ATM programs, 3 shelf registrations and 1 completed offering on file for NXTC. The latest dilution event on file is ATM sales on Jun 30, 2026. Analysis updated Oct 7, 2026.
Signal8 Summary
NXTC
Pending merger, near-zero cash runway
Snapshot
NextCure is a clinical-stage biotech burning cash rapidly with no revenue. The structured data shows a cash runway of just 1.5 months, indicating immediate liquidity concerns despite a balance sheet listing $41.8M in cash.
What's Happening Right Now
- : NextCure agreed to merge with privately-held Avere Therapeutics, changing its name to Avere Therapeutics and ticker to AVRX, with current NextCure stockholders retaining approximately 1.21% of the combined company.
- : NextCure reported positive Phase 1 dose escalation data for SIM0505 at ASCO 2026, showing a 55% objective response rate in gynecologic cancers and 52.9% in ovarian cancer.
- : The company announced FDA Fast Track designation for SIM0505 for platinum-resistant ovarian cancer and reported Q1 cash of $29.7 million, sufficient to fund operations into the first half of 2027.
